

CITATION REPORT

List of articles citing

A Pan-Cancer Proteogenomic Atlas of PI3K/AKT/mTOR Pathway Alterations

DOI: 10.1016/j.ccell.2017.04.013
Cancer Cell, 2017, 31, 820-832.e3.

Source: <https://exaly.com/paper-pdf/66385448/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
369	SGK1 Is a Critical Component of an AKT-Independent Pathway Essential for PI3K-Mediated Tumor Development and Maintenance. 2017 , 77, 6914-6926		21
368	Oncogenic Activities of IDH1/2 Mutations: From Epigenetics to Cellular Signaling. 2017 , 27, 738-752		67
367	Precision Medicine: Progress, Pitfalls, and Promises. 2017 , 16, 2641-2644		5
366	Drug repurposing for the treatment of glioblastoma multiforme. 2017 , 36, 169		40
365	A network modeling approach to elucidate drug resistance mechanisms and predict combinatorial drug treatments in breast cancer. 2017 , 1, 5		33
364	Phosphorylation of AKT and ERK1/2 and mutations of PIK3CA and PTEN are predictive of breast cancer cell sensitivity to everolimus in vitro. 2018 , 81, 745-754		12
363	Integrated Genomic and Immunophenotypic Classification of Pancreatic Cancer Reveals Three Distinct Subtypes with Prognostic/Predictive Significance. 2018 , 24, 4444-4454		96
362	Oncogenic Signaling Pathways in The Cancer Genome Atlas. 2018 , 173, 321-337.e10		1124
361	Reciprocal Signaling between Glioblastoma Stem Cells and Differentiated Tumor Cells Promotes Malignant Progression. 2018 , 22, 514-528.e5		110
360	A Landscape of Metabolic Variation across Tumor Types. 2018 , 6, 301-313.e3		73
359	Pan-Cancer Molecular Classes Transcending Tumor Lineage Across 32 Cancer Types, Multiple Data Platforms, and over 10,000 Cases. 2018 , 24, 2182-2193		49
358	Making Use of Cancer Genomic Databases. 2018 , 121, 19.14.1-19.14.13		7
357	Phosphoglyceric acid mutase-1 contributes to oncogenic mTOR-mediated tumor growth and confers non-small cell lung cancer patients with poor prognosis. 2018 , 25, 1160-1173		34
356	Protein restriction and cancer. 2018 , 1869, 256-262		31
355	Osthole inhibits the PI3K/AKT signaling pathway via activation of PTEN and induces cell cycle arrest and apoptosis in esophageal squamous cell carcinoma. 2018 , 102, 502-509		36
354	Long noncoding RNA DANCR mediates cisplatin resistance in glioma cells via activating AXL/PI3K/Akt/NF- κ B signaling pathway. 2018 , 118, 233-241		67
353	Effect of PI3K/Akt/mTOR signaling pathway on JNK3 in Parkinsonian rats. 2019 , 17, 1771-1775		7

352	Long Non-Coding RNA XLOC_006753 Promotes the Development of Multidrug Resistance in Gastric Cancer Cells Through the PI3K/AKT/mTOR Signaling Pathway. 2018 , 51, 1221-1236		35
351	mTOR signalling and cellular metabolism are mutual determinants in cancer. 2018 , 18, 744-757		334
350	Integrated Analysis of Genetic Ancestry and Genomic Alterations across Cancers. <i>Cancer Cell</i> , 2018 , 34, 549-560.e9	24.3	78
349	Energy Stress-Mediated Cytotoxicity in Tuberous Sclerosis Complex 2-Deficient Cells with Nelfinavir and Mefloquine Treatment. <i>Cancers</i> , 2018 , 10,	6.6	2
348	Cancer-Associated PIK3CA Mutations in Overgrowth Disorders. 2018 , 24, 856-870		112
347	Organoid Profiling Identifies Common Responders to Chemotherapy in Pancreatic Cancer. <i>Cancer Discovery</i> , 2018 , 8, 1112-1129	24.4	394
346	Resistance to Systemic Therapies in Clear Cell Renal Cell Carcinoma: Mechanisms and Management Strategies. 2018 , 17, 1355-1364		98
345	mTOR and Tumor Cachexia. 2018 , 19,		19
344	Phosphoinositide 3-Kinase Signaling Pathway in Pancreatic Ductal Adenocarcinoma Progression, Pathogenesis, and Therapeutics. 2018 , 9, 335		46
343	A cytoplasmic long noncoding RNA LINC00470 as a new AKT activator to mediate glioblastoma cell autophagy. 2018 , 11, 77		47
342	BRD4 amplification facilitates an oncogenic gene expression program in high-grade serous ovarian cancer and confers sensitivity to BET inhibitors. 2018 , 13, e0200826		28
341	Heterogeneity of Phosphatidylinositol-3-Kinase (PI3K)/AKT/Mammalian Target of Rapamycin Activation in Cancer: Is PI3K Isoform Specificity Important?. <i>Frontiers in Oncology</i> , 2017 , 7, 330	5.3	13
340	VHL and Hypoxia Signaling: Beyond HIF in Cancer. 2018 , 6,		48
339	Somatic mutation profiling of vulvar cancer: Exploring therapeutic targets. 2018 , 150, 552-561		29
338	Selective eradication of cancer displaying hyperactive Akt by exploiting the metabolic consequences of Akt activation. 2018 , 7,		20
337	Signal-Targeted Therapies and Resistance Mechanisms in Pancreatic Cancer: Future Developments Reside in Proteomics. <i>Cancers</i> , 2018 , 10,	6.6	7
336	A Pan-Cancer Compendium of Genes Deregulated by Somatic Genomic Rearrangement across More Than 1,400 Cases. 2018 , 24, 515-527		49
335	Targeting the Hsp90-Cdc37-client protein interaction to disrupt Hsp90 chaperone machinery. 2018 , 11, 59		31

334	Personalization of prostate cancer therapy through phosphoproteomics. 2018 , 15, 483-497		21
333	Targeting the CDK4/6-Rb Pathway Enhances Response to PI3K Inhibition in -Mutant Lung Squamous Cell Carcinoma. 2018 , 24, 5990-6000		10
332	The clinical applications of The Cancer Genome Atlas project for bladder cancer. 2018 , 18, 973-980		9
331	Simultaneously targeting DNA damage repair pathway and mTORC1/2 results in small cell lung cancer growth arrest via ER stress-induced apoptosis. 2018 , 14, 1221-1231		7
330	TFEB Mediates Immune Evasion and Resistance to mTOR Inhibition of Renal Cell Carcinoma via Induction of PD-L1. 2019 , 25, 6827-6838		30
329	DMBT1 suppresses progression of gallbladder carcinoma through PI3K/AKT signaling pathway by targeting PTEN. 2019 , 83, 2257-2264		5
328	A phase Ib, open-label, dose-escalation study of the safety and pharmacology of taselisib (GDC-0032) in combination with either docetaxel or paclitaxel in patients with HER2-negative, locally advanced, or metastatic breast cancer. 2019 , 178, 121-133		4
327	Serine and one-carbon metabolism, a bridge that links mTOR signaling and DNA methylation in cancer. 2019 , 149, 104352		17
326	Topological integration of RPPA proteomic data with multi-omics data for survival prediction in breast cancer via pathway activity inference. 2019 , 12, 94		1
325	Targeting the complexity of Src signalling in the tumour microenvironment of pancreatic cancer: from mechanism to therapy. 2019 , 286, 3510-3539		21
324	Integrative multi-omics analysis identifies a prognostic miRNA signature and a targetable miR-21-3p/TSC2/mTOR axis in metastatic pheochromocytoma/paraganglioma. 2019 , 9, 4946-4958		30
323	The Modulatory Properties of Treatment on Triple-Negative Breast Cancer: An Integrated Pharmacological Method. <i>Frontiers in Pharmacology</i> , 2019 , 10, 1171	5.6	17
322	An immunoevasive strategy through clinically-relevant pan-cancer genomic and transcriptomic alterations of JAK-STAT signaling components. 2019 , 25, 46		9
321	HIF-mediated Suppression of DEPTOR Confers Resistance to mTOR Kinase Inhibition in Renal Cancer. 2019 , 21, 509-520		9
320	Double mutations in cis increase oncogenicity and sensitivity to PI3K inhibitors. 2019 , 366, 714-723		102
319	eIF4A Inhibitors Suppress Cell-Cycle Feedback Response and Acquired Resistance to CDK4/6 Inhibition in Cancer. 2019 , 18, 2158-2170		14
318	Proteogenomics: From next-generation sequencing (NGS) and mass spectrometry-based proteomics to precision medicine. 2019 , 498, 38-46		25
317	Triptolide Induces Glioma Cell Autophagy and Apoptosis via Upregulating the ROS/JNK and Downregulating the Akt/mTOR Signaling Pathways. <i>Frontiers in Oncology</i> , 2019 , 9, 387	5.3	20

316	Development of Personalized Therapeutic Strategies by Targeting Actionable Vulnerabilities in Metastatic and Chemotherapy-Resistant Breast Cancer PDXs. 2019 , 8,	7
315	Deoxyshikonin isolated from inhibits colorectal cancer by down-regulating the PI3K/Akt/mTOR pathway. 2019 , 57, 412-423	17
314	LIM and SH3 protein 1 induces glioma growth and invasion through PI3K/AKT signaling and epithelial-mesenchymal transition. 2019 , 116, 109013	17
313	Emerging Role of SOX Proteins in Breast Cancer Development and Maintenance. 2019 , 24, 213-230	8
312	Celastrol mediates autophagy and apoptosis via the ROS/JNK and Akt/mTOR signaling pathways in glioma cells. 2019 , 38, 184	57
311	Mouse Models for Exploring the Biological Consequences and Clinical Significance of Mutations. 2019 , 9,	7
310	Diverse signaling mechanisms of mTOR complexes: mTORC1 and mTORC2 in forming a formidable relationship. 2019 , 72, 51-62	100
309	Targeting the PI3-kinase pathway in triple-negative breast cancer. 2019 , 30, 1051-1060	86
308	Advances in understanding the mechanisms of evasive and innate resistance to mTOR inhibition in cancer cells. 2019 , 1866, 1322-1337	10
307	Metabolic functions of macropinocytosis. 2019 , 374, 20180285	39
306	PI3K/AKT/mTOR Pathway Alterations Promote Malignant Progression and Xenograft Formation in Oligodendroglial Tumors. 2019 , 25, 4375-4387	16
305	Rebound pathway overactivation by cancer cells following discontinuation of PI3K or mTOR inhibition promotes cancer cell growth. 2019 , 513, 546-552	2
304	Molecular subtype classification of papillary renal cell cancer using miRNA expression. 2019 , 12, 2311-2322	1
303	Emerging role of PI3K/AKT in tumor-related epigenetic regulation. 2019 , 59, 112-124	57
302	Oncogenic promotes cellular stemness in an allele dose-dependent manner. 2019 , 116, 8380-8389	31
301	Tumor Suppressor miRNA-204-5p Regulates Growth, Metastasis, and Immune Microenvironment Remodeling in Breast Cancer. 2019 , 79, 1520-1534	83
300	mTOR Signaling in Cancer and mTOR Inhibitors in Solid Tumor Targeting Therapy. 2019 , 20,	219
299	PIK3CA in cancer: The past 30 years. 2019 , 59, 36-49	65

298	Mammalian Target of Rapamycin: A Metabolic Rheostat for Regulating Adipose Tissue Function and Cardiovascular Health. 2019 , 189, 492-501		12
297	Tanshinone IIA enhances the inhibitory effect of imatinib on proliferation and motility of acute leukemia cell line TIB-152 in vivo and in vitro by inhibiting the PI3K/AKT/mTOR signaling pathway. 2020 , 43, 503-515		4
296	Cellular and Genetic Determinants of the Sensitivity of Cancer to β -Particle Irradiation. 2019 , 79, 5640-5651		13
295	ZDOG: zooming in on dominating genes with mutations in cancer pathways. <i>BMC Bioinformatics</i> , 2019 , 20, 740	3.6	1
294	Overview of the relevance of PI3K pathway in HR-positive breast cancer. 2019 , 30, x3-x11		43
293	RADAR: differential analysis of MeRIP-seq data with a random effect model. 2019 , 20, 294		16
292	Pan-cancer molecular subtypes revealed by mass-spectrometry-based proteomic characterization of more than 500 human cancers. <i>Nature Communications</i> , 2019 , 10, 5679	17.4	150
291	Targeting mTOR and Metabolism in Cancer: Lessons and Innovations. 2019 , 8,		77
290	Molecular Correlates of Metastasis by Systematic Pan-Cancer Analysis Across The Cancer Genome Atlas. 2019 , 17, 476-487		15
289	Urolithin A, a Novel Natural Compound to Target PI3K/AKT/mTOR Pathway in Pancreatic Cancer. 2019 , 18, 301-311		31
288	Connecting Proteomics to Next-Generation Sequencing: Proteogenomics and Its Current Applications in Biology. 2019 , 19, e1800235		21
287	A comprehensive overview of oncogenic pathways in human cancer. 2020 , 21, 957-969		10
286	Identification and characterization of a BRAF fusion oncoprotein with retained autoinhibitory domains. 2020 , 39, 814-832		10
285	The influence of patient sex on clinical approaches to malignant glioma. <i>Cancer Letters</i> , 2020 , 468, 41-47	9.9	12
284	PTEN expression and mutations in TSC1, TSC2 and MTOR are associated with response to rapalogs in patients with renal cell carcinoma. 2020 , 146, 1435-1444		8
283	Keratin 17 activates AKT signalling and induces epithelial-mesenchymal transition in oesophageal squamous cell carcinoma. 2020 , 211, 103557		15
282	The PI3K-AKT network at the interface of oncogenic signalling and cancer metabolism. 2020 , 20, 74-88		434
281	Osthole induces cell cycle arrest and apoptosis in head and neck squamous cell carcinoma by suppressing the PI3K/AKT signaling pathway. 2020 , 316, 108934		9

280	Selective targeting of the DEAD-box RNA helicase eukaryotic initiation factor (eIF) 4A by natural products. 2020 , 37, 609-616	21
279	Cracking the context-specific PI3K signaling code. 2020 , 13,	23
278	Medulloblastoma genomics in the modern molecular era. 2020 , 30, 679-690	20
277	Dual mTORC1/2 Inhibition Sensitizes Testicular Cancer Models to Cisplatin Treatment. 2020 , 19, 590-601	5
276	Proteomic signatures of clear cell renal cell carcinoma. 2020 , 16, 133-134	3
275	PI3K/AKT/mTOR signaling as a molecular target in head and neck cancer. 2020 , 172, 113729	85
274	Predicting mechanism of action of cellular perturbations with pathway activity signatures. 2020 , 36, 4781-4788	4
273	Hydroxysafflor Yellow A Attenuates Hydrogen Peroxide-Induced Oxidative Damage on Human Umbilical Vein Endothelial Cells. 2020 , 2020, 8214128	1
272	Oncogenic activation of PI3K-AKT-mTOR signaling suppresses ferroptosis via SREBP-mediated lipogenesis. 2020 , 117, 31189-31197	112
271	Genomic landscape analyses in cervical carcinoma and consequences for treatment. 2020 , 54, 142-157	1
270	Serum and Glucocorticoid-Inducible Kinase 1 (SGK1) in NSCLC Therapy. 2020 , 13,	2
269	Characterization of tumors with ultralow tumor mutational burden in Japanese cancer patients. 2020 , 111, 3893-3901	6
268	Androgen receptor and uterine histoarchitecture in a PCOS rat model. 2020 , 518, 110973	1
267	Autophagy, the innate immune response and cancer. 2020 , 14, 1913-1929	26
266	The Underlying Tumor Genomics of Predominant Histologic Subtypes in Lung Adenocarcinoma. 2020 , 15, 1844-1856	20
265	Phosphatidylinositol-3-OH kinase signalling is spatially organized at endosomal compartments by microtubule-associated protein 4. 2020 , 22, 1357-1370	7
264	ISL Induces Apoptosis and Autophagy in Hepatocellular Carcinoma via Downregulation of PI3K/AKT/mTOR Pathway in vivo and in vitro. 2020 , 14, 4363-4376	7
263	PI3K-AKT-mTOR pathway alterations in advanced NSCLC patients after progression on EGFR-TKI and clinical response to EGFR-TKI plus everolimus combination therapy. 2020 , 9, 1258-1267	18

262	Body fatness and mTOR pathway activation of breast cancer in the Women's Circle of Health Study. 2020 , 6, 45	4
261	Integrated Genomic Characterization of the Human Immunome in Cancer. 2020 , 80, 4854-4867	4
260	PIK3CA C-terminal frameshift mutations are novel oncogenic events that sensitize tumors to PI3K inhibition. 2020 , 117, 24427-24433	6
259	ERCC6L promotes the progression of hepatocellular carcinoma through activating PI3K/AKT and NF- κ B signaling pathway. 2020 , 20, 853	3
258	Prognostic significance of SOCS1 and SOCS3 tumor suppressors and oncogenic signaling pathway genes in hepatocellular carcinoma. 2020 , 20, 774	3
257	An integrative pan-cancer investigation reveals common genetic and transcriptional alterations of AMPK pathway genes as important predictors of clinical outcomes across major cancer types. 2020 , 20, 773	4
256	Human embryonic stem cell-derived organoid retinoblastoma reveals a cancerous origin. 2020 , 117, 33628-33636	3
255	Eukaryotic translation initiation factors as promising targets in cancer therapy. 2020 , 18, 175	9
254	Cinobufagin Triggers Defects in Spindle Formation and Cap-Dependent Translation in Liver Cancer Cells by Inhibiting the AURKA-mTOR-eIF4E Axis. 2020 , 48, 651-678	6
253	Molecular mechanisms mediating relapse following ivosidenib monotherapy in IDH1-mutant relapsed or refractory AML. 2020 , 4, 1894-1905	62
252	Targeting AKT/mTOR in Oral Cancer: Mechanisms and Advances in Clinical Trials. 2020 , 21,	59
251	Living-donor liver transplantation for liver hemorrhaging due to peliosis hepatis in X-linked myotubular myopathy: Two cases and a literature review. 2020 , 20, 2606-2611	4
250	Molecular patterns in salivary duct carcinoma identify prognostic subgroups. 2020 , 33, 1896-1909	2
249	The Pan-Omics Landscape of Renal Cell Carcinoma and Its Implication on Future Clinical Practice. 2020 , 4, 121-129	1
248	mTOR Signaling and SREBP Activity Increase FADS2 Expression and Can Activate Sapienate Biosynthesis. 2020 , 31, 107806	15
247	Metformin as an Alternative Radiosensitizing Agent to 5-Fluorouracil During Neoadjuvant Treatment for Rectal Cancer. 2020 , 63, 918-926	11
246	2,6-DMBQ is a novel mTOR inhibitor that reduces gastric cancer growth in vitro and in vivo. 2020 , 39, 107	6
245	Fentanyl inhibits the progression of gastric cancer through the suppression of MMP-9 via the PI3K/Akt signaling pathway. 2020 , 8, 118	11

244	(3E,5E)-3,5-Bis(pyridin-3-methylene)-tetrahydrothiopyran-4-one enhances the inhibitory effect of gemcitabine on pancreatic cancer cells. 2020 , 101, 104022	2
243	Activating PIK3CA mutation promotes osteogenesis of bone marrow mesenchymal stem cells in macrodactyly. 2020 , 11, 505	6
242	Lycopene Inhibits Epithelial-Mesenchymal Transition and Promotes Apoptosis in Oral Cancer via PI3K/AKT/m-TOR Signal Pathway. 2020 , 14, 2461-2471	15
241	Molecular characterization of chromophobe renal cell carcinoma reveals mTOR pathway alterations in patients with poor outcome. 2020 , 33, 2580-2590	9
240	Identification of the Mutational Landscape of Gynecological Malignancies. 2020 , 11, 4870-4883	8
239	Is There a Role for Dual PI3K/mTOR Inhibitors for Patients Affected with Lymphoma?. 2020 , 21,	12
238	Epigenetically silenced LINC02381 functions as a tumor suppressor by regulating PI3K-Akt signaling pathway. 2020 , 171-172, 63-71	15
237	Design, Synthesis, and Biological Evaluation of Imidazo[1,2-]pyridine Derivatives as Novel PI3K/mTOR Dual Inhibitors. 2020 , 63, 3028-3046	27
236	PIK3CA variants selectively initiate brain hyperactivity during gliomagenesis. 2020 , 578, 166-171	50
235	Shear stress activates ATOH8 via autocrine VEGF promoting glycolysis dependent-survival of colorectal cancer cells in the circulation. 2020 , 39, 25	18
234	High-coverage whole-genome analysis of 1220 cancers reveals hundreds of genes deregulated by rearrangement-mediated cis-regulatory alterations. <i>Nature Communications</i> , 2020 , 11, 736	17.4 32
233	AQP5 enriches for stem cells and cancer origins in the distal stomach. 2020 , 578, 437-443	34
232	ANXA6 Contributes to Radioresistance by Promoting Autophagy via Inhibiting the PI3K/AKT/mTOR Signaling Pathway in Nasopharyngeal Carcinoma. 2020 , 8, 232	12
231	Understanding oncogenicity of cancer driver genes and mutations in the cancer genomics era. 2020 , 594, 4233-4246	6
230	PLS3 predicts poor prognosis in pancreatic cancer and promotes cancer cell proliferation via PI3K/AKT signaling. 2020 , 235, 8416-8423	5
229	Modulation of the PI3K/mTOR pathways. 2020 , 89-105	
228	Tumor cell- and microenvironment-specific roles of cysteine cathepsins in mouse models of human cancers. 2020 , 1868, 140423	8
227	Pan-cancer analysis reveals synergistic effects of CDK4/6i and PARPi combination treatment in RB-proficient and RB-deficient breast cancer cells. 2020 , 11, 219	4

226	Whole-genome sequencing reveals distinct genetic bases for insulinomas and non-functional pancreatic neuroendocrine tumours: leading to a new classification system. 2020 , 69, 877-887		41
225	Phase I Basket Study of Taselisib, an Isoform-Selective PI3K Inhibitor, in Patients with -Mutant Cancers. 2021 , 27, 447-459		13
224	Chromophobe renal cell carcinoma: current and controversial issues. 2021 , 53, 101-108		11
223	Reciprocal REG β mTORC1 regulation promotes glycolytic metabolism in hepatocellular carcinoma. 2021 , 40, 677-692		2
222	Phase III randomized study of tasisib or placebo with fulvestrant in estrogen receptor-positive, PIK3CA-mutant, HER2-negative, advanced breast cancer: the SANDPIPER trial. 2021 , 32, 197-207		34
221	In Vivo Evidence for Serine Biosynthesis-Defined Sensitivity of Lung Metastasis, but Not of Primary Breast Tumors, to mTORC1 Inhibition. 2021 , 81, 386-397.e7		18
220	Granulocyte-colony stimulating factor-producing uterine cervical cancer treated with chemoradiotherapy: A case report with mutation analysis and literature review. 2021 , 9, 185-192		0
219	Expression profile of immune checkpoint genes and their roles in predicting immunotherapy response. 2021 , 22,		25
218	PTEN deficiency leads to proteasome addiction: a novel vulnerability in glioblastoma. 2021 , 23, 1072-1086		2
217	Metabolic Codependencies in the Tumor Microenvironment. <i>Cancer Discovery</i> , 2021 , 11, 1067-1081	24.4	24
216	Baicalin Induces Apoptosis and Suppresses the Cell Cycle Progression of Lung Cancer Cells Through Downregulating Akt/mTOR Signaling Pathway. <i>Frontiers in Molecular Biosciences</i> , 2020 , 7, 602282	5.6	8
215	Update on the role of copanlisib in hematologic malignancies. 2021 , 12, 20406207211006027		2
214	MRPS17 promotes invasion and metastasis through PI3K/AKT signal pathway and could be potential prognostic marker for gastric cancer. 2021 , 12, 4849-4861		2
213	Integrated Genomic and Transcriptomic Analysis reveals key genes for predicting dual-phenotype Hepatocellular Carcinoma Prognosis. 2021 , 12, 2993-3010		2
212	Real world clinicopathologic observations of patients with metastatic solid tumors receiving immune checkpoint inhibitor therapy: Analysis from Kentucky Cancer Registry. 2021 , 10, 2054-2062		1
211	LncRNA DNAJC3-AS1 Regulates Fatty Acid Synthase the EGFR Pathway to Promote the Progression of Colorectal Cancer. <i>Frontiers in Oncology</i> , 2020 , 10, 604534	5.3	5
210	MNS1 promotes hepatocarcinogenesis and metastasis via activating PI3K/AKT by translocating Ectenin and predicts poor prognosis. 2021 , 41, 1409-1420		2
209	Mass-spectrometry-based proteomic correlates of grade and stage reveal pathways and kinases associated with aggressive human cancers. 2021 , 40, 2081-2095		8

208	Recent Advances in Integrative Multi-Omics Research in Breast and Ovarian Cancer. 2021 , 11,	5
207	The State-of-the-Art of Phase II/III Clinical Trials for Targeted Pancreatic Cancer Therapies. 2021 , 10,	8
206	MiR-1539 and Its Potential Role as a Novel Biomarker for Colorectal Cancer. <i>Frontiers in Oncology</i> , 2020 , 10, 531244	5-3 3
205	Chemical composition and pharmacological mechanism of ephedra-glycyrrhiza drug pair against coronavirus disease 2019 (COVID-19). 2021 , 13, 4811-4830	10
204	Growth and Viability of Cutaneous Squamous Cell Carcinoma Cell Lines Display Different Sensitivities to Isoform-Specific Phosphoinositide 3-Kinase Inhibitors. 2021 , 22,	1
203	Chemical Phosphoproteomics Sheds New Light on the Targets and Modes of Action of AKT Inhibitors. 2021 , 16, 631-641	5
202	Signaling Pathways in Cancer: Therapeutic Targets, Combinatorial Treatments, and New Developments. 2021 , 10,	13
201	Multimiomics integrative analysis reveals antagonistic roles of CBX2 and CBX7 in metabolic reprogramming of breast cancer. 2021 , 15, 1450-1465	7
200	Organismal roles for the PI3K and Isoforms: their specificity, redundancy or cooperation is context-dependent. 2021 , 478, 1199-1225	2
199	miR-654-5p inhibits autophagy by targeting ATG7 via mTOR signaling in intervertebral disc degeneration. 2021 , 23,	2
198	Exosome component 1 cleaves single-stranded DNA and sensitizes kidney renal clear cell carcinoma cells to poly(ADP-ribose) polymerase inhibitor.	
197	From Oncogenic Signaling Pathways to Single-Cell Sequencing of Immune Cells: Changing the Landscape of Cancer Immunotherapy. 2021 , 26,	19
196	SOX4 and SMARCA4 cooperatively regulate PI3k signaling through transcriptional activation of TGFBR2. 2021 , 7, 40	3
195	Chaetocochin J, an epipolythiodioxopiperazine alkaloid, induces apoptosis and autophagy in colorectal cancer via AMPK and PI3K/AKT/mTOR pathways. 2021 , 109, 104693	5
194	Kaempferol induces ROS-dependent apoptosis in pancreatic cancer cells via TGM2-mediated Akt/mTOR signaling. 2021 , 21, 396	9
193	Beta-Elemene Reduces the Malignancy of Non-Small Cell Lung Cancer by Enhancing Expression. <i>Frontiers in Oncology</i> , 2021 , 11, 571476	5-3 1
192	The therapeutic landscape of hepatocellular carcinoma.. 2021 , 2, 505-552	3
191	Pancreatic cancer intrinsic PI3K activity accelerates metastasis and rewires macrophage component. 2021 , 13, e13502	3

190	Feed-forward activation of STAT3 signaling limits the efficacy of c-Met inhibitors in esophageal squamous cell carcinoma (ESCC) treatment. 2021 , 60, 481-496		1
189	The Mixed Blessing of AMPK Signaling in Cancer Treatments.		
188	PI3K inhibitors are finally coming of age. 2021 , 20, 741-769		45
187	mTORC1 and ferroptosis: Regulatory mechanisms and therapeutic potential. 2021 , 43, e2100093		7
186	Molecular and morphological changes induced by ivosidenib correlate with efficacy in mutant-cholangiocarcinoma. 2021 , 17, 2057-2074		6
185	Survival prediction based on the gene expression associated with cancer morphology and microenvironment in primary central nervous system lymphoma. 2021 , 16, e0251272		0
184	Attacking the PI3K/Akt/mTOR signaling pathway for targeted therapeutic treatment in human cancer. 2021 ,		15
183	Exosome component 1 cleaves single-stranded DNA and sensitizes human kidney renal clear cell carcinoma cells to poly(ADP-ribose) polymerase inhibitor. 2021 , 10,		2
182	Properties of FDA-approved small molecule phosphatidylinositol 3-kinase inhibitors prescribed for the treatment of malignancies. 2021 , 168, 105579		13
181	In Silico and In Cell Hybrid Selection of Nonrapalog Ligands to Allosterically Inhibit the Kinase Activity of mTORC1. 2021 ,		4
180	RASSF1A independence and early Galectin-1 upregulation in PIK3CA induced hepatocarcinogenesis: new therapeutic venues.		
179	Body fatness and breast cancer risk in relation to phosphorylated mTOR expression in a sample of predominately Black women. 2021 , 23, 77		
178	NRF-1 directly regulates TFE3 and promotes the proliferation of renal cancer cells. 2021 , 22, 679		0
177	Regulation and metabolic functions of mTORC1 and mTORC2. 2021 , 101, 1371-1426		33
176	Pinocembrin Inhibits the Proliferation and Metastasis of Breast Cancer Suppression of the PI3K/AKT Signaling Pathway. <i>Frontiers in Oncology</i> , 2021 , 11, 661184	5.3	2
175	Autoimmune Responses in Oncology: Causes and Significance. 2021 , 22,		2
174	Metabolic Reprogramming: A Friend or Foe to Cancer Therapy?. <i>Cancers</i> , 2021 , 13,	6.6	2
173	VHL suppresses RAPTOR and inhibits mTORC1 signaling in clear cell renal cell carcinoma. 2021 , 11, 14827		3

172	Osthole suppresses the proliferation and induces apoptosis via inhibiting the PI3K/AKT signaling pathway of endometrial cancer JEC cells. 2021 , 22, 1171		1
171	Prognostic significance and tumor-immune infiltration of mTOR in clear cell renal cell carcinoma. 2021 , 9, e11901		2
170	-Related Overgrowth Spectrum From Diagnosis to Targeted Therapy: A Case of CLOVES Syndrome Treated With Alpelisib. 2021 , 9, 732836		4
169	A forward genetic screen identifies modifiers of rocaglate responsiveness. 2021 , 11, 18516		1
168	Targeting Mps1 in combination with paclitaxel inhibits osteosarcoma progression by modulating spindle assembly checkpoint and Akt/mTOR signaling. 2021 , 22, 797		0
167	Targeting PI3K Pathway in Pancreatic Ductal Adenocarcinoma: Rationale and Progress. <i>Cancers</i> , 2021 , 13,	6.6	3
166	Combined Scutellarin and CHNO Imperils the Survival of Glioma: Partly Associated With the Repression of PSEN1/PI3K-AKT Signaling Axis. <i>Frontiers in Oncology</i> , 2021 , 11, 663262	5.3	0
165	Identification of a Ferroptosis-Related Signature Model Including mRNAs and lncRNAs for Predicting Prognosis and Immune Activity in Hepatocellular Carcinoma. <i>Frontiers in Oncology</i> , 2021 , 11, 738477	5.3	9
164	Blockade of mutant RAS oncogenic signaling with a special emphasis on KRAS. 2021 , 172, 105806		7
163	First-in-child phase I/II study of the dual mTORC1/2 inhibitor vistusertib (AZD2014) as monotherapy and in combination with topotecan-temozolomide in children with advanced malignancies: arms E and F of the AcSESMART trial. 2021 , 157, 268-277		3
162	The role of mTOR in age-related diseases. 2021 , 36, 1679-1693		6
161	Mutational Landscape of PI3K-AKT-mTOR Pathway in Breast Cancer: Implications for Targeted Therapeutics. 2021 , 12, 4408-4417		4
160	Major Molecular Signaling Pathways in Oral Cancer Associated With Therapeutic Resistance.. 2020 , 1, 603160		8
159	The Roles of Cullin-2 E3 Ubiquitin Ligase Complex in Cancer. 2020 , 1217, 173-186		6
158	Activating AKT1 and PIK3CA Mutations in Metastatic Castration-Resistant Prostate Cancer. 2020 , 78, 834-844		23
157	PD-L1 regulates tumorigenesis and autophagy of ovarian cancer by activating mTORC signaling. 2019 , 39,		9
156	The Genomic Landscape of Prostate Cancer Brain Metastases.		2
155	Large-scale Characterization of Drug Responses of Clinically Relevant Proteins in Cancer Cell Lines.		1

154	Transcriptomically-inferred PI3K activity and stemness show a counterintuitive correlation with PIK3CA genotype in breast cancer.	2
153	Biological insights from the whole genome analysis of human embryonic stem cells.	2
152	An integrative pan-cancer investigation reveals common genetic and transcriptional alterations of AMPK pathway genes as important predictors of clinical outcomes across major cancer types.	1
151	Connecting omics signatures of diseases, drugs, and mechanisms of actions with iLINCS.	21
150	RADAR: Differential analysis of MeRIP-seq data with a random effect model.	1
149	PTEN-opathies: from biological insights to evidence-based precision medicine. 2019 , 129, 452-464	78
148	Tuberous sclerosis complex-associated CNS abnormalities depend on hyperactivation of mTORC1 and Akt. 2018 , 128, 1688-1706	17
147	Autocrine CXCL8-dependent invasiveness triggers modulation of actin cytoskeletal network and cell dynamics. 2020 , 12, 1928-1951	9
146	Mechanistic target of rapamycin inhibitors: successes and challenges as cancer therapeutics.. 2019 , 2, 1069-1085	2
145	Long noncoding RNA UCA1 facilitates cell proliferation and inhibits apoptosis in retinoblastoma by activating the PI3K/Akt pathway.. 2020 , 9, 1012-1022	2
144	Potential relationship between Sirt3 and autophagy in ovarian cancer. 2020 , 20, 162	4
143	Ginsenoside CK induces apoptosis and suppresses proliferation and invasion of human osteosarcoma cells through the PI3K/mTOR/p70S6K1 pathway. 2020 , 43, 886-896	11
142	FoxO suppresses endoplasmic reticulum stress to inhibit growth of Tsc1-deficient tissues under nutrient restriction. 2020 , 9,	2
141	Prognostic significance of PI3K/AKT/ mTOR signaling pathway members in clear cell renal cell carcinoma. 2020 , 8, e9261	11
140	The Lipid Kinase PI3Ks Required for the Cohesion and Survival of Cancer Cells Disseminated in Serous Cavities.	
139	Identification of Pathway-Based Biomarkers with Crosstalk Analysis for Overall Survival Risk Prediction in Breast Cancer. 2021 , 12, 689715	
138	Improving the Genome Annotation of Using Proteogenomics.. 2021 , 22, 373-383	0
137	Loss of epigenetic regulation disrupts lineage integrity, reactivates multipotency and promotes breast cancer.	0

136	Combinatorial tumor suppressor inactivation efficiently initiates lung adenocarcinoma with therapeutic vulnerabilities.	
135	A network modeling approach to elucidate drug resistance mechanisms and predict combinatorial drug treatments in breast cancer.	
134	Oncogenic PIK3CA promotes cellular stemness in an allele dose-dependent manner.	1
133	Biology of Pancreas and Possible Diseases. 2019 , 1-25	
132	Predicting mechanism of action of cellular perturbations with pathway activity signatures.	0
131	The lipid kinase PI3Ks required for the cohesion and survival of cancer cells disseminated in serous cavities.	
130	Prognostic significance of SOCS1 and SOCS3 tumor suppressors in hepatocellular carcinoma and its correlation to key oncogenic signaling pathways.	
129	Comprehensive and Integrated Genomic Characterization of Human Immunome in Cancer.	
128	Multomics integrative analysis reveals antagonistic roles of CBX2 and CBX7 in metabolic reprogramming of breast cancer.	
127	Cell line-specific network models of ER+ breast cancer identify PI3K inhibitor sensitivity factors and drug combinations.	
126	Activation of oxidative phosphorylation in TP53-inactive endometrial carcinomas with a poor prognosis. 2021 , 31, 1557-1563	1
125	Proteomic profiling of bladder cancer for precision medicine in the clinical setting: A review for the busy urologist. 2020 , 61, 539-554	2
124	Crosstalk of Molecular Signaling in Hepatocellular Carcinoma. 2020 , 85-94	0
123	Discovery of novel putative tumor suppressors from CRISPR screens reveals rewired lipid metabolism in AML cells.	
122	Pancreatic Cancer Intrinsic PI3K Activity accelerates Metastasis and rewires Macrophage Component.	
121	Therapeutic implications of activating noncanonical PIK3CA mutations in head and neck squamous cell carcinoma. 2021 , 131,	0
120	Positive correlation between transcriptomic stemness and PI3K/AKT/mTOR signaling scores in breast cancer, and a counterintuitive relationship with PIK3CA genotype. 2021 , 17, e1009876	0
119	Discovery of putative tumor suppressors from CRISPR screens reveals rewired lipid metabolism in acute myeloid leukemia cells. <i>Nature Communications</i> , 2021 , 12, 6506	17.4 2

118	RASSF1A independence and early galectin-1 upregulation in PIK3CA-induced hepatocarcinogenesis: new therapeutic venues. 2021 ,		1
117	Copy number alterations and epithelial-mesenchymal transition genes in diffuse and intestinal gastric cancers in Mexican patients.		
116	Diverse Roles and Therapeutic Potentials of Circular RNAs in Urological Cancers. <i>Frontiers in Molecular Biosciences</i> , 2021 , 8, 761698	5.6	0
115	EBV LMP1-activated mTORC1 and mTORC2 Coordinately Promote Nasopharyngeal Cancer Stem Cell Formation.		
114	Metabolic Oxidative Stress in Initiation, Progression, and Therapy of Cancer. 2021 , 1-35		
113	Dietary Carotenoids in Head and Neck Cancer-Molecular and Clinical Implications.. 2022 , 14,		3
112	EBV LMP1-activated mTORC1 and mTORC2 Coordinately Promote Nasopharyngeal Cancer Stem Cell Properties.. 2022 , jvi0194121		0
111	Mutational pattern of PIK3CA exon 20 in circulating DNA in breast cancer.. 2022 , 29, 2828-2835		0
110	Wnt and PI3K/Akt/mTOR Survival Pathways as Therapeutic Targets in Glioblastoma.. 2022 , 23,		5
109	IFN- γ affects pancreatic cancer properties by MACC1-AS1/MACC1 axis via AKT/mTOR signaling pathway.. 2022 , 1		1
108	Mutations in Diffuse Gliomas: An Update on Molecular Stratification, Prognosis, Recurrence, and Aggressiveness.. 2022 , 16, 11795549211068804		0
107	The mixed blessing of AMPK signaling in Cancer treatments.. 2022 , 22, 105		2
106	The cholesterol pathway: impact on immunity and cancer.. 2022 , 43, 78-92		3
105	Pan-Cancer DNA Methylation Analysis and Tumor Origin Identification of Carcinoma of Unknown Primary Site Based on Multi-Omics.. 2021 , 12, 798748		0
104	Splice-switching of the insulin receptor pre-mRNA alleviates tumorigenic hallmarks in rhabdomyosarcoma.. 2022 , 6, 1		1
103	Molecular design of dual inhibitors of PI3K and potential molecular target of cancer for its treatment: A review. 2021 , 228, 114039		2
102	Functional impact and targetability of , , and mutations in a spindle cell rhabdomyosarcoma with MYOD1 L122R mutation.. 2022 , 8,		3
101	Metabolic Oxidative Stress in Initiation, Progression, and Therapy of Cancer. 2022 , 1969-2003		

100	Synergistic inhibitory effect of ßhumulene and sclareol on human pancreatic cancer cells. 2022 , 89, 104958		
99	lncRNA SNHG26 promoted the growth, metastasis, and cisplatin resistance of tongue squamous cell carcinoma through PGK1/Akt/mTOR signal pathway.. 2022 , 24, 355-370		1
98	Activating PIK3CA postzygotic mutations in segmental overgrowth of muscles with bone involvement in the body extremities.. 2022 , 1		0
97	Disentangling the signaling pathways of mTOR complexes, mTORC1 and mTORC2, as a therapeutic target in glioblastoma.. 2021 , 100854		0
96	The Interplay Between the Transcriptomics and Proteomics Profiles. 2022 , 187-208		0
95	Systematic Pan-Cancer Analysis Reveals Molecular Characteristics and Clinical Relevance of Serine/Arginine-Rich Splicing Factors in Human Cancers.		
94	Hepatocellular carcinoma after a sustained virological response by direct-acting antivirals harbors TP53 inactivation.. 2022 ,		1
93	The critical function of metabolic reprogramming in cancer metastasis. 2022 , 3, 20-43		0
92	PIK3CA co-occurring mutations and copy-number gain in hormone receptor positive and HER2 negative breast cancer.. 2022 , 8, 24		1
91	Oncogenic Pathways in Neurodegenerative Diseases.. 2022 , 23,		1
90	PI3K/Akt/mTOR Pathway and Its Role in Cancer Therapeutics: Are We Making Headway?. <i>Frontiers in Oncology</i> , 2022 , 12, 819128	5-3	17
89	Targeting oncogene and non-oncogene addiction to inflame the tumour microenvironment.. 2022 ,		7
88	PI3K/AKT/mTOR signaling pathway activity in IDH-mutant diffuse glioma and clinical implications.. 2022 ,		0
87	Copy number alterations and epithelial-mesenchymal transition genes in diffuse and intestinal gastric cancers in Mexican patients.. 2022 , 25,		
86	Targeting ferroptosis as a vulnerability in cancer.. 2022 ,		31
85	Epigenetic enzyme mutations as mediators of anti-cancer drug resistance.. 2022 , 61, 100821		2
84	Resistance to mutant IDH inhibitors in acute myeloid leukemia: Molecular mechanisms and therapeutic strategies.. <i>Cancer Letters</i> , 2022 , 215603	9-9	0
83	An amino acid-defined diet impairs tumour growth in mice by promoting endoplasmic reticulum stress and mTOR inhibition.. 2022 , 101478		0

82	On the Road to Accurate Protein Biomarkers in Prostate Cancer Diagnosis and Prognosis: Current Status and Future Advances.. 2021 , 22,		2
81	Impact of cancer metabolism on therapy resistance - Clinical implications.. 2021 , 100797		3
80	Sera from women with different metabolic and menopause states differentially regulate cell viability and Akt activation in a breast cancer in-vitro model.. 2022 , 17, e0266073		0
79	AKT mutant allele-specific activation dictates pharmacologic sensitivities.. <i>Nature Communications</i> , 2022 , 13, 2111	17.4	2
78	Data_Sheet_1.PDF. 2020 ,		
77	Table_1.xlsx. 2020 ,		
76	Table_2.xlsx. 2020 ,		
75	Table_3.xlsx. 2020 ,		
74	Table_1.doc. 2019 ,		
73	Table_2.xls. 2019 ,		
72	Table_3.doc. 2019 ,		
71	Data_Sheet_1.docx. 2019 ,		
70	The roles of E3 ligases in Hepatocellular carcinoma.. 2022 , 12, 1179-1214		
69	Network Pharmacology-Based Prediction and Verification of Ginsenoside Rh2-Induced Apoptosis of A549 Cells via the PI3K/Akt Pathway. <i>Frontiers in Pharmacology</i> , 2022 , 13,	5.6	0
68	Genome-Scale Metabolic Model Analysis of Metabolic Differences between Lauren Diffuse and Intestinal Subtypes in Gastric Cancer.. <i>Cancers</i> , 2022 , 14,	6.6	0
67	High incidence of PI3K pathway gene mutations in South Indian cervical cancers.. <i>Cancer Genetics</i> , 2022 , 264-265, 100-108	2.3	
66	Proteogenomic characterization of 2002 human cancers reveals pan-cancer molecular subtypes and associated pathways.. <i>Nature Communications</i> , 2022 , 13, 2669	17.4	3
65	Machine learning approach informs biology of cancer drug response.. <i>BMC Bioinformatics</i> , 2022 , 23, 184	3.6	1

64	Targeting DEAD-box RNA helicases: The emergence of molecular staples.. <i>Wiley Interdisciplinary Reviews RNA</i> , 2022 , e1738	9.3	0
63	Detection of a novel panel of 24 genes with high frequencies of mutation in gastric cancer based on next-generation sequencing. <i>World Journal of Clinical Cases</i> , 2022 , 10, 4761-4775	1.6	
62	The WHO 2022 landscape of papillary and chromophobe renal cell carcinoma. <i>Histopathology</i> ,	7.3	0
61	mTOR pathway gene expression in association with race and clinicopathological characteristics in Black and White breast cancer patients. <i>Discover Oncology</i> , 2022 , 13,		1
60	Kinase inhibitors for precision therapy of triple-negative breast cancer: Progress, challenges, and new perspectives on targeting this heterogeneous disease. <i>Cancer Letters</i> , 2022 , 215775	9.9	0
59	Targeting p85 nuclear translocation for the tumors with PIK3CA helical domain mutations. <i>Genes and Diseases</i> , 2022 ,	6.6	
58	Inhibiting PI3K/AKT/mTOR Signaling in Multiple Myeloma-Associated Mesenchymal Stem Cells Impedes the Proliferation of Multiple Myeloma Cells. <i>Frontiers in Oncology</i> , 12,	5.3	0
57	RNF43 G659fs is an oncogenic colorectal cancer mutation and sensitizes tumor cells to PI3K/mTOR inhibition. <i>Nature Communications</i> , 2022 , 13,	17.4	1
56	In missed abortion the decrease of IGF-1 down-regulates PI3K/AKT signaling pathway reducing the secretion of progesterone and hCG. <i>Growth Hormone and IGF Research</i> , 2022 , 65, 101479	2	
55	Alpelisib monotherapy for PI3K-altered, pre-treated advanced breast cancer: a phase 2 study. <i>Cancer Discovery</i> ,	24.4	1
54	The Mechanisms of Ferroptosis and the Applications in Tumor Treatment: Enemies or Friends?. <i>Frontiers in Molecular Biosciences</i> , 9,	5.6	0
53	Integrating network pharmacology and experimental models to investigate the efficacy of QYHJ on pancreatic cancer. <i>Journal of Ethnopharmacology</i> , 2022 , 297, 115516	5	0
52	The promising therapeutic effects of metformin on metabolic reprogramming of cancer-associated fibroblasts in solid tumors. 2022 , 27,		1
51	Selective suppression of melanoma lacking IFN- γ pathway by JAK inhibition depends on T cells and host TNF signaling. 2022 , 13,		1
50	Connecting omics signatures and revealing biological mechanisms with iLINCS. 2022 , 13,		1
49	A novel glycosylated indolocarbazole derivative LCS1269 effectively inhibits growth of human cancer cells in vitro and in vivo through driving of both apoptosis and senescence by inducing of DNA damage and modulating of AKT/mTOR/S6K and ERK pathways. 2022 , 364, 110056		1
48	Vitamin E TPGS-Poloxamer Nanoparticles Entrapping a Novel PI3K Inhibitor Potentiate Its Activity against Breast Cancer Cell Lines. 2022 , 14, 1977		0
47	Pan-genomic analysis shows hemizygous PTEN loss tumors are associated with immune evasion and poor outcome.		0

- 46 Comparison of dual mTORC1/2 inhibitor AZD8055 and mTORC1 inhibitor rapamycin on the metabolism of breast cancer cells using proton nuclear magnetic resonance spectroscopy metabolomics. ○
- 45 Loss of epigenetic regulation disrupts lineage integrity, induces aberrant alveogenesis and promotes breast cancer. ○
- 44 LOT and HOT ... or not. The proliferation of clinically insignificant and poorly characterised types of renal neoplasia. **2022**, ○
- 43 Systemic explanation of Glycyrrhiza glabra analyzed compounds and anti-cancer mechanism based on network pharmacology in oral cancer. **2022**, ○
- 42 The WW domain of IQGAP1 binds directly to the p110 catalytic subunit of PI 3-kinase. ○
- 41 Linear ubiquitination of PTEN impairs its function to promote prostate cancer progression. 2
- 40 Discovery of 2-Methyl-2-(4-(2-methyl-8-(1H-pyrrolo[2,3-b]pyridin-6-yl)-1H-naphtho[1,2-d]imidazol-1-yl)phenyl)propanenitrile as a Novel PI3K/mTOR Inhibitor with Enhanced Antitumor Efficacy In Vitro and In Vivo.
- 39 Non-genomic activation of the AKT-mTOR pathway by the mitochondrial stress response in thyroid cancer. ○
- 38 PI3K/AKT signaling pathway as a critical regulator of Cisplatin response in tumor cells. **2021**, 29, 235-250 ○
- 37 AKT Isoforms as a Target in Cancer and Immunotherapy. **2022**, 409-436 ○
- 36 Involvement of the p53-p16/RB pathway control mechanism in early-stage carcinogenesis in head and neck squamous cell carcinoma. ○
- 35 Development of PI3K inhibitors for tumor therapy. 1-18 2
- 34 Aberrant Signaling Pathways in Cancer. 1-10 ○
- 33 Prevalencia de la mutación de PIK3CA en cáncer de mama en la Argentina y su asociación con variables clínico-patológicas. **2022**, 26, ○
- 32 PIK3CA Mutational Analysis in Patients With Macroductyly. 109352662210801 ○
- 31 Inaugurating a novel adjuvant therapy in urological cancers: Ferroptosis. **2022**, ○
- 30 Towards a potential pan-cancer prognostic signature for gene expression based on probesets and ensemble machine learning. **2022**, 15, ○
- 29 Role of Tumor Suppressor PTEN and Its Regulation in Malignant Transformation of Endometrium. **2022**, 87, 1310-1326 ○

- 28 Refining sugar β involvement in cholesterol synthesis. **2023**, 1868, 159266 ○
- 27 Moquiniastrum polymorphum subsp. polymorphum extract inhibits the proliferation of an activated hepatic stellate cell line (GRX) by regulating the p27 pathway to generate cell cycle arrest. **2023**, 303, 116056 ○
- 26 Antibody reliability influences observed mRNA-protein correlations in tumour samples. ○
- 25 PI3K / AKT pathway promotes keloid fibroblasts proliferation by enhancing glycolysis under hypoxia. ○
- 24 Clinical proteomics towards multiomics in cancer. 1
- 23 Immune Pathways with Aging Characteristics Improve Immunotherapy Benefits and Drug Prediction in Human Cancer. **2023**, 15, 342 ○
- 22 Crosstalk between protein kinases AKT and ERK1/2 in human lung tumor-derived cell models. 12, ○
- 21 Traditional Chinese medicine for transformation of gastric precancerous lesions to gastric cancer: A critical review. 15, 36-54 ○
- 20 MAOA suppresses the growth of gastric cancer by interacting with NDRG1 and regulating the Warburg effect through the PI3K/AKT/mTOR pathway. ○
- 19 Gene Expression Profiles in Cancers and Their Therapeutic Implications. **2023**, 29, 9-14 ○
- 18 Molecular Aspects and Therapeutic Implications of Herbal Compounds Targeting Different Types of Cancer. **2023**, 28, 750 1
- 17 Multiple Mutations within Individual Oncogenes: Examples and Clinical Implications. **2023**, ○
- 16 Rational combination of SHP2 and mTOR inhibition for the treatment of hepatocellular carcinoma. ○
- 15 PI5P4K β supports prostate cancer metabolism and exposes a survival vulnerability during androgen receptor inhibition. **2023**, 9, ○
- 14 Interfering with the Ubiquitin-Mediated Regulation of Akt as a Strategy for Cancer Treatment. **2023**, 24, 2809 ○
- 13 Papillary Intralymphatic Angioendothelioma in a Child With PIK3CA-Related Overgrowth Spectrum: Implication of PI3K Pathway in the Vascular Tumorigenesis. **2023**, 26, 166-171 ○
- 12 Recurrent PIK3CA H1047R-Mutated Congenital Infiltrative Facial Lipomatosis: A Case Report and Review of Literature. **2023**, 45, 1712-1719 ○
- 11 Phosphoinositide 3-Kinase (PI3K) Inhibitors and Breast Cancer: An Overview of Current Achievements. **2023**, 15, 1416 ○

- 10 Mesenchymal stem cells in the treatment of spinal cord injury: Mechanisms, current advances and future challenges. 14, ○
- 9 Uncovering the mechanism of Kang-ai injection for treating intrahepatic cholangiocarcinoma based on network pharmacology, molecular docking, and in vitro validation. 14, ○
- 8 Discovering Synergistic Compounds with BYL-719 in PI3K Overactivated Basal-like PDXs. **2023**, 15, 1582 ○
- 7 Immunotherapy or targeted therapy: What will be the future treatment for anaplastic thyroid carcinoma?. 13, ○
- 6 PIK3CA copy number gain and inhibitors of the PI3K/AKT/mTOR pathway in triple-negative breast cancer. mcs.a006255 ○
- 5 The emerging role of PI3K inhibitors for solid tumour treatment and beyond. ○
- 4 PIK3CA and PIK3R1 tumor mutational landscape in a pan-cancer patient cohort and its association with pathway activation and treatment efficacy. **2023**, 13, ○
- 3 Pan-cancer genomic analysis shows hemizygous PTEN loss tumors are associated with immune evasion and poor outcome. **2023**, 13, ○
- 2 Ethyl Acetate Extract of *Halymenia durvillei* Induced Apoptosis, Autophagy, and Cell Cycle Arrest in Colorectal Cancer Cells. **2023**, 28, 69-78 ○
- 1 Sulconazole induces PANoptosis by triggering oxidative stress and inhibiting glycolysis to increase radiosensitivity in esophageal cancer. **2023**, 100551 ○